UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~July~~December 1727, 2012 (~~July~~December 2321, 2012)

InferX Corporation

(Exact name of registrant as specified in its charter)

Delaware	0-51720	54-1614664
(State of other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

46950 Jennings Farm Drive
Suite 290, Sterling, VA		20164
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (703) 444-6030

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~July~~December 1721, 2012, ~~Vijay~~ ~~Suri,~~Paul B. Silverman was appointed as President and CEO of the registrant ("InferX"), and aboth ~~member~~Paul ofB. ~~its~~Silverman ~~Board~~and ofCarl B. ~~Directors,~~Eckstein ~~resigned~~were aselected ~~President~~by ~~and CEO~~the ~~and~~current ~~from~~sole Board member, B.K. Gogia, to the Board of Directors of InferX to fill vacancies on the Board. B.K. Gogia, the founder of InferX, remains as Chairman of the Board and has ~~assumed~~resigned the positions of Acting President and CEO of InferX. ~~Mr. Gogia intends to form a new management team for InferX.~~

~~Item~~Paul B. 5Silverman, 68, has for the last five years provided business consulting services, most recently serving as Managing Partner for the Gemini Group, LLC, a firm providing consulting services to emerging technology companies.01 ~~Changes~~From May 2008 through December 2008 Mr. Silverman was interim President and CEO of InferX. Mr. Silverman is an experienced entrepreneur, public company CEO, global corporate management advisor and senior corporate management executive. He is also an adjunct faculty member at the R.H. Smith School of Business at the University of Maryland. Mr. Silverman has a diversified and successful track record spanning more than 30 years, including 19 years in ~~Control~~senior corporate management with RCA Corporation, Xerox Corporation, GTE and Satellite Business Systems (a division of ~~Registrant~~IBM) in areas of international management and marketing, strategic planning and international business development, and nine years in senior management consulting with Coopers and Lybrand, Booz Allen and Hamilton and James Martin Strategy, Inc. where he served as CEO for North America. Mr. Silverman holds a Bachelor of Science degree in Physics from City College of New York and an Master of Science degree in Management from Polytechnic University of New York.

ACarl ~~change~~B. inEckstein, ~~control~~73, ofhas ~~InferX~~served ~~occurred~~ as aManaging ~~result~~Partner of aSundial ~~dilutive issuance of shares on December 1~~Ventures, ~~2010 that was not disclosed to two holders of debentures issued by InferX~~LLC, ~~Fourth~~a ~~Street~~business ~~Fund,~~development ~~LP ("FSF") and Rahul Argade~~firm, ~~an employee of InferX. InferX had sold 1,000,000 shares of common stock in December 2010 to an investor~~ for ~~$0.002 per share. This sale triggered rights under~~ the ~~debentures~~last tofive ~~convert debt into common stock at the same price~~years. ~~On December 23, 2009, FSF entered into a Debenture and Warrant Purchase Agreement with InferX (“FSF Purchase Agreement”)~~Mr. ~~Pursuant~~Eckstein ~~to the FSF Purchase Agreement, InferX issued FSF an 8% Secured Convertible~~also ~~Debenture~~has ~~for~~served ~~the~~as ~~principal~~Managing ~~sum~~Director of ~~$150,000~~NextGen ~~(the~~Capital ~~“FSF~~I ~~Debenture”). Similarly, on April 19, 2010, Argade entered into a Debenture~~ and ~~Warrant~~II ~~Purchase~~venture ~~Agreement~~capital ~~with~~funds ~~InferX~~that ~~(“Agrade~~have ~~Purchase~~made ~~Agreement”)~~equity ~~and~~investments ~~pursuant~~in ~~to the Argade Purchase~~private ~~Agreement,~~emerging ~~InferX~~technology ~~issued~~companies. ~~Argade~~In anthis 8%role ~~Secured~~he ~~Convertible~~has ~~Debenture~~directly ~~for~~participated ~~the~~in ~~principal~~22 ~~sum~~investments ~~of $100,000 dated April 19, 2010 (the “Argade Debenture”). The FSF Debenture~~ and ~~the~~in ~~Argade~~some ~~Debenture~~cases ~~(together~~served ~~“the~~as ~~Debentures”)~~CEO ~~have identical terms regarding the conversion~~ of ~~the debt into InferX common stock. The Debentures were convertible into shares of common stock~~several atportfolio ~~a conversion price equal to $0~~companies.20 ~~per share (the “Initial Conversion Price”)~~Mr. ~~The~~Eckstein ~~Debentures~~has ~~also~~over ~~provided~~thirty ~~that, in~~years ~~the~~of ~~event~~experience ~~InferX~~as ~~sold any common stock or other equity securities at an effective price per share that was lower than the Initial Conversion Price (~~a ~~“Dilutive~~venture ~~Issuance”)~~capitalist, ~~the~~consultant ~~Initial~~and ~~Conversion Price for~~ the ~~Debenture~~owner ~~holders~~of ~~would be reduced to~~several ~~the~~software ~~lower~~firms ~~price~~engaged ~~per share charged~~ in ~~connection~~GIS ~~with~~and ~~the~~information ~~Dilutive~~technology ~~Issuance~~consulting. InMr. ~~addition,~~Eckstein’s ~~the~~experience ~~Debentures~~also ~~obligated~~includes ~~InferX~~serving toas ~~provide~~a toprincipal ~~FSF~~with ~~written~~Arthur ~~notice~~Young, ofconsultant aat ~~Dilutive~~Price ~~Issuance (the “Dilutive Issuance Notice”)~~Waterhouse, ~~which notice was required to include the issuance price~~ and ~~other~~a ~~pricing~~systems ~~terms,~~engineer ~~within~~at ~~one~~IBM. ~~business~~Mr. ~~day~~Eckstein ~~following~~has ~~such~~a anBachelor ~~issuance. Regardless~~ of ~~whether InferX sent~~Science ~~the~~degree ~~required~~in ~~Dilutive~~Microbiology ~~Issuance~~from ~~Notice,~~Ohio ~~the~~State Debentures provided that the Debenture holders would automatically be entitled to receive the number of common stock at the Base Conversion Price for all conversions done on or the after the occurrence of a Dilutive IssuanceUniversity.

~~Without~~InferX ~~knowledge of~~has ~~the~~granted ~~Dilutive~~to ~~Issuance~~Mr. Silverman 15,000,000 ~~FSF~~performance-based ~~sent~~warrants ~~notices~~to acquire shares of ~~conversion~~InferX oncommon ~~January~~stock ~~19,~~at ~~2011,~~an ~~May~~exercise 19price of $0.03 per share that are exercisable for five years to vest as follows: 3 million warrants upon raising a minimum of $200,000 ~~2011~~in ~~and~~equity ~~December~~investment; 52 million warrants upon InferX reporting minimum quarterly revenues of $800,000 ~~2011~~for two consecutive quarters; 2 million warrants upon InferX reporting minimum quarterly revenues of $1.25 Onmillion ~~each~~for ~~occasion,~~two consecutive quarters; 2 million warrants upon InferX ~~honored~~achieving ~~FSF’s~~a ~~conversion~~minimum ~~request~~market ~~but~~capitalization ~~utilized~~(defined as the ~~Initial~~average closing ~~Conversion~~price ~~Price~~for InferX's common stock times the number of ~~$0.20~~its ~~instead~~issued shares of ~~the~~common ~~Base~~stock ~~Conversion~~on a fully diluted basis) of ~~price~~$10 million for 14 consecutive days; 3 million warrants upon InferX achieving a minimum market capitalization of $015 million for 14 consecutive days; and 3 million warrants upon InferX raising a minimum of $2 million in equity or debt financings.~~002~~ InferX ~~per~~has ~~share~~granted to Mr. AsEckstein a400,000 ~~result~~shares of InferX’s ~~failure~~common stock to ~~apply~~serve ~~the~~as ~~Base~~a ~~Conversion~~member ~~Price~~of tothe ~~FSF’s~~Board ~~conversions~~of onDirectors. ~~January~~As ~~19,~~compensation ~~2011,~~to ~~May~~serve ~~19,~~as ~~2011~~a ~~and~~Senior ~~December 5~~Advisor, ~~2011,~~Mr. ~~InferX~~Eckstein ~~failed~~was granted a warrant to ~~issue~~purchase 57for five years 600,~~737,870~~000 shares of InferX's common stock ~~due~~at toan ~~FSF~~exercise ~~under~~price of $.03 per share which vest at 150,000 shares per quarter ~~the~~during ~~FSF~~his ~~Debenture~~term of service commencing March 31, 2013.

On– ~~June~~1 17, 2012, Rahul Argade notified InferX and Vijay Suri that he was converting $20,000 of principal and $21,397 in interest due into InferX common stock. Applying the Base Conversion Price that resulted from the Dilutive Issuance, InferX should have issued Rahul Argade 20,698,615 shares.–

~~FSF~~InferX ~~has~~issued ~~elected~~a ~~to receive~~press ~~only~~release ~~22.52%~~to orannounce the ~~13,000,000~~appointment of ~~the~~Paul ~~shares due the Fund and to release InferX from any financial damages incurred~~B. ~~The Fund~~ ~~has~~Silverman ~~offered~~as toan ~~place~~officer ~~77.48%~~and ordirector ~~44,737,870~~ of the ~~shares~~company ~~due~~and ~~FSF~~Carl ~~into~~B. ~~escrow~~Eckstein ~~for~~as ~~InferX~~a todirector ~~use~~of ~~to secure~~ the ~~necessary financing, incentivize additional management talent and make acquisitions~~company. A ~~percentage~~copy of the ~~escrowed~~press ~~shares~~release tois beattached ~~mutually agreed~~ to ~~will~~this beCurrent ~~cancelled~~Report ~~upon~~on ~~the~~Form ~~settlement~~8-K ~~of outstanding~~as ~~debt~~Exhibit ~~and past due salaries, certain intellectual property and patent enhancement of its current software products, and future financings~~99.1.

~~Rahul~~Item ~~Argade has elected to receive only 51~~9.~~68%~~01 orExhibits ~~10,698,615 of the shares due to him~~ and toFinancial ~~release InferX from any financial damages incurred.~~ Statements

~~Immediately~~(d) prior to the issuance of the shares of InferX common stock under the Debentures, there are 20,669,453 shares issued and outstanding of which Vijay Suri owned 9,779,768 shares or 48.9% of the issued and outstanding shares of InferX. Following the conversion of the Debentures there will be 44,368,068 shares of InferX common stock issued and outstanding. FSF will own 13,250,000 shares directly, excluding the 44,737,870 escrowed shares discussed above.Exhibits

~~SIGNATURES~~99.1 Press release dated December 27, 2012

~~Pursuant~~– to2 ~~the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~–

Date: July 23, 2012	InferX Corporation
	By:	/s/ B.K. Gogia
		B.K. GogiaActing President and CEO

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: December 27, 2012	InferX Corporation

	By:	/s/ Paul B. Silverman
		Paul B. Silverman
		President and CEO

Filing Compare · INFERX CORP